PMID- 24950857
OWN - NLM
STAT- MEDLINE
DCOM- 20150331
LR  - 20210504
IS  - 1976-3786 (Electronic)
IS  - 0253-6269 (Linking)
VI  - 37
IP  - 8
DP  - 2014 Aug
TI  - Clinical implication of SGLT2 inhibitors in type 2 diabetes.
PG  - 957-66
LID - 10.1007/s12272-014-0419-0 [doi]
AB  - Treatment of type 2 diabetes mellitus (T2DM) continues to present challenges, 
      with many patients failing to achieve glycemic targets. Despite the availability 
      of many oral and injectable anti-diabetic agents, therapeutic efficacy is often 
      offset by undesirable side effects such as hypoglycemia, weight gain and 
      cardiovascular complications. Therefore, the search for new therapeutic agents 
      with an improved benefit-risk profile continues. Recent research has focused on 
      the kidney as a potential therapeutic target, especially because maximal renal 
      glucose reabsorption is increased in T2DM. Under normal physiological conditions, 
      nearly all filtered glucose is reabsorbed in the proximal tubule of the nephron 
      via the sodium/glucose co-transporter 2 (SGLT2). SGLT2-inhibitors are a new class 
      of oral anti-diabetes, which reduce hyperglycemia by increasing urinary glucose 
      excretion independently of insulin secretion or action. Canagliflozin and 
      dapagliflozin in US market, and ipragliflozin and luseogliflozin in Japan market 
      are now available for glycemic control in type 2 diabetics. There are several 
      phase III clinical ongoing trials involving this new class of medications. This 
      review examines some of the key efficacy and safety data from clinical trials of 
      the SGLT2 inhibitors approved, and their future perspectives in the treatment of 
      T2DM.
FAU - Kim, Go Woon
AU  - Kim GW
AD  - Department of Pharmacology and Clinical Pharmacy, College of Pharmacy, Kyung Hee 
      University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Republic of Korea.
FAU - Chung, Sung Hyun
AU  - Chung SH
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140621
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - 506T60A25R (Sorbitol)
RN  - C596HWF74Z 
      (1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Administration, Oral
MH  - Benzhydryl Compounds/administration & dosage/adverse 
      effects/pharmacology/therapeutic use
MH  - Canagliflozin
MH  - Clinical Trials, Phase III as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucose/metabolism
MH  - Glucosides/administration & dosage/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Insulin/metabolism
MH  - Kidney/drug effects/metabolism
MH  - Molecular Structure
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Sorbitol/administration & dosage/adverse effects/analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Thiophenes/administration & dosage/adverse effects/pharmacology/therapeutic use
EDAT- 2014/06/22 06:00
MHDA- 2015/04/01 06:00
CRDT- 2014/06/22 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/05/31 00:00 [accepted]
PHST- 2014/06/22 06:00 [entrez]
PHST- 2014/06/22 06:00 [pubmed]
PHST- 2015/04/01 06:00 [medline]
AID - 10.1007/s12272-014-0419-0 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2014 Aug;37(8):957-66. doi: 10.1007/s12272-014-0419-0. Epub 2014 
      Jun 21.